Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion's Shares Spike to Lead Nasdaq

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of molecular diagnostics firm Vermillion rose 23 percent on Monday to close at $8.95, leading all gainers on the Nasdaq for the day.

The reason for the spike is unclear, as the firm didn't disclose any news or file any documents with the US Securities and Exchange Commission. Trading in the firm's shares also was heavy, with 603,100 shares trading hands, compared to its average daily volume of around 128,000.

Vermillion emerged from Chapter 11 bankruptcy protection early in 2010. The firm has since been relisted on Nasdaq and recently inked a new deal with Quest Diagnostics, the company's sales and marketing partner for the OVA1 test.

Vermillion's share price has nearly doubled this month, since its close of $4.79 on Nov. 30.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.